Cancer drug design and discovery

書誌事項

Cancer drug design and discovery

edited by Stephen Neidle

Academic Press, 2008

大学図書館所蔵 件 / 4

この図書・雑誌をさがす

注記

Includes bibliographical references and index

内容説明・目次

内容説明

The ultimate source of information on the design of new anticancer agents, emphasizing small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumors. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of drug design. Appealing to a broad audience, this is an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry and clinicians taking oncology options.

目次

Section I. Basic Principles 1. Modern cancer drug discovery: Integrating targets, technologies and treatments 2. Preclinical pharmacology and in vivo models 3. Clinical trial designs for more rapid proof-of-principle and approval Section II. Methodology 4. Structural biology and anticancer drug design 5. Natural product chemistry and cancer drug discovery 6. Pharmacokinetics & ADME optimization in drug discovery Section III. Drugs in the clinic and laboratory 7. Temozolomide: from cytotoxic to molecularly-targeted agent 8. Camptothecins for drug design, cancer cell death and gene targeting 9. Targeting thymidylate synthase by antifolate drugs for the treatment of cancer Section IV. New Agents 10. Targeting inactive kinases: structure as a foundation for cancer drug discovery 11. Cell cycle inhibitors in cancer: current status and future directions 12. Inhibition of DNA repair as a therapeutic target 13. Heat shock protein-90 inhibitors: targeting the cancer chaperone for combinatorial blockade of oncogenic pathways 14. Heat shock protein-90-directed therapeutics and target validation 15. Inhibitors of tumour angiogenesis 16. The biology and oncology of RAF-ERK signalling P53 as a therapeutic target Section V. The reality of cancer drugs in the clinic 17. Cancer drug resistance 18. Failure Modes in Anticancer Drug Discovery and Development

「Nielsen BookData」 より

詳細情報

ページトップへ